Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06150820 · ClinicalTrials.gov registry record · NA
A Study About Antibody Levels and Biomarkers in the Blood in People With Late-onset Pompe Disease
A NA study of Pompe Disease (Late-onset), sponsored by Astellas Gene Therapies.
- Active
- Registry status
- NA
- Development phase
- 119
- Enrollment target
- 20
- Study locations
NCT06150820 is a NA study of Pompe Disease (Late-onset) that is active but no longer recruiting, run by Astellas Gene Therapies. The registered enrollment target is 119 participants, above the 32-participant average among 8 other Pompe Disease (Late-onset) trials with a reported enrollment target (272% higher). The trial reports 20 study locations across 10 states.
The verdict
NCT06150820, a NA study of Pompe Disease (Late-onset), is active but no longer recruiting, sponsored by Astellas Gene Therapies.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 119 participants
- Enrollment target
- 20
- Study locations
Study Summary
Pompe disease is a genetic condition which causes muscle weakness over time. People with Pompe disease have a faulty gene that makes an enzyme called acid alpha-glucosidase (or GAA). This enzyme breaks down a type of sugar called glycogen. Without this enzyme, there is a build-up of glycogen in the cells of the body. This causes muscle weakness and other symptoms. Pompe disease can happen at any age, but in late-onset Pompe disease, symptoms generally start from 12 months old onwards. The standard treatment for people with Pompe disease is to receive regular infusions of the GAA enzyme. This is known as enzyme replacement therapy. However, people can build up antibodies against the GAA enzyme over time. Gene therapy is used to treat conditions caused by a faulty gene. It works by replacing the faulty gene with a working gene inside the cells of the body. The working gene is delivered into the cells using certain viruses as carriers (vectors). Viruses are often used as carriers as they can easily get inside cells. The genetic material of the original virus is replaced with the working gene, so only the working gene gets inside the cells. A common virus used as a carrier in gene therapy is the adeno-associated virus (or AAV). This is like an adenovirus, which causes the common cold. The original type of AAV does not cause any harm to humans. However, people that have previously been infected with the original type of AAV may have built up antibodies against AAV. These antibodies may stop the AAV carrier with the working gene getting inside the cells. Researchers want to learn more about antibody levels against AAV and the GAA enzyme in people with late-onset Pompe disease. They also want to learn about other substances in the blood that provide more information about late-onset Pompe disease. These are known as biomarkers. In this study, older teenagers and adults with late-onset Pompe disease will take part. They will not have had gene therapy using AAV. There w
Conditions Studied
Interventions
- OTHER No Intervention
Study Locations (20)
Other
- AU61003 - Adelaide
- AU61001 - Herston
- BR55003 - Flamengo
- BR55002 - Porto Alegre
- BR55001 - São Paulo
- CN15003 - Edmonton
- CA15001 - Montreal
- FR33006 - Angers
- FR33009 - Garches
- FR33005 - Lille
Pennsylvania
- University of Pennsylvania - Philadelphia
- University of Pittsburgh Medical Center - Pittsburgh
Georgia
- Emory Clinic - Atlanta
Kansas
- University of Kansas Medical Center - Kansas City
Michigan
- University of Michigan - Ann Arbor
Minnesota
- Children's Hospitals and Clinics of Minnesota - Minneapolis
New Jersey
- Hackensack University Medical Center - Hackensack
Ohio
- University of Cincinnati - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2024-02-01 |
| Est. Completion | 2027-06-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06150820
The ClinicalTrials.gov registry entry for NCT06150820 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 119 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 32-participant average among 8 other Pompe Disease (Late-onset) trials with a reported enrollment target (272% higher). The listed sponsor is Astellas Gene Therapies, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pompe Disease (Late-onset) appearing as the primary indexed condition, and to 1 intervention - of which No Intervention is the first listed.
NCT06150820 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Other, Pennsylvania, Georgia.
Frequently Asked Questions
What is clinical trial NCT06150820 about?
NCT06150820 is a clinical study titled "A Study About Antibody Levels and Biomarkers in the Blood in People With Late-onset Pompe Disease". Pompe disease is a genetic condition which causes muscle weakness over time. People with Pompe disease have a faulty gene that makes an enzyme called acid alpha-glucosidase (or GAA). This enzyme breaks down a type of sugar called glycogen. Without this enzyme, there is a build-up of glycogen in the ...
What is the current status of trial NCT06150820?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 119 participants. The study started on 2024-02-01. Estimated completion is 2027-06-30.
What conditions does trial NCT06150820 study?
This clinical trial studies the following conditions: Pompe Disease (Late-onset).
What interventions are being tested in trial NCT06150820?
The interventions under investigation include: No Intervention (OTHER).
Who is sponsoring clinical trial NCT06150820?
This trial is sponsored by Astellas Gene Therapies, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06150820 being conducted?
This trial has 20 study locations across Georgia, Kansas, Michigan, Minnesota, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pompe Disease (Late-onset)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pompe Pregnancy Sub-Registry
RECRUITING
-
A Study to Evaluate Safety, Tolerability, and Efficacy of AB-1009 Gene Therapy (GAA Gene) in Adult Participants With Late Onset Pompe Disease (PROGRESS-GT LOPD)
RECRUITING · Phase 1
-
ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPD
ACTIVE NOT RECRUITING · Phase 3
-
A Gene Transfer Study for Late-Onset Pompe Disease (RESOLUTE)
ACTIVE NOT RECRUITING · Phase 1
-
Developing a Management Approach for Patients With "Late-Onset" Pompe Disease
ACTIVE NOT RECRUITING
-
Gene Transfer Study in Patients With Late Onset Pompe Disease
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.